ALX Oncology Faces Delisting Notice

Ticker: ALXO · Form: 8-K · Filed: Apr 25, 2025 · CIK: 1810182

Sentiment: bearish

Topics: delisting, listing-standards, regulatory

Related Tickers: ALXO

TL;DR

ALXO got a delisting notice, stock might be in trouble.

AI Summary

ALX Oncology Holdings Inc. filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective April 23, 2025. The company is incorporated in Delaware and its principal executive offices are located at 323 Allerton Avenue, South San Francisco, California.

Why It Matters

This filing indicates potential issues with ALX Oncology's continued listing on a stock exchange, which could significantly impact its stock price and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock viability and investor confidence.

Key Players & Entities

FAQ

What specific listing rule or standard did ALX Oncology fail to satisfy?

The filing does not specify the exact rule or standard that ALX Oncology failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

What is the effective date of the notice of delisting or failure to satisfy a continued listing rule?

The earliest event reported, which is the date of the notice, is April 23, 2025.

What is the company's ticker symbol?

The filing does not explicitly state the ticker symbol, but the company name is ALX Oncology Holdings Inc.

What is the company's primary business sector?

The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].

Where are ALX Oncology's principal executive offices located?

ALX Oncology's principal executive offices are located at 323 Allerton Avenue, South San Francisco, California 94080.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 25, 2025 regarding ALX ONCOLOGY HOLDINGS INC (ALXO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing